Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Neurogene Inc.Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK, October 05, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company’s common stock to five new employees (the "Inducement Grants") on October 5, 2026 (the "Grant Date"). The Induce
- McKinney Launches L.E.A.P. to Rethink Patient Advocacy and Ambassador EngagementMcKinney Health is launching L.E.A.P (Living Experience Ambassador Programs), a new patient advocacy practice led by Laura Catalusci, MA, MCHES.
- Zag Bio™, Inc.Zag Bio Advances ZAG-101 into Clinical Development for Type 1 DiabetesCAMBRIDGE, Mass., October 05, 2026--Zag Bio™, Inc., a biotechnology company working to set a new standard for treating autoimmune disease, today announced it has advanced its lead program for Type 1 diabetes (T1D), ZAG-101, into clinical development. The company’s first-in-human Phase 1b/2a clinical trial (LANTERN) will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZAG-101 and explore its potential to preserve insulin-producing beta-cell function.
- Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)Company announcement No. 53 / 2026
- Massachusetts Nurses AssociationMNA: Brigham Nurses File 4th Unfair Labor Practice Charge Against the Hospital as Nurses Prepare for October 14th Indefinite Strike and MGB Refuses to Negotiate a Fair Contract to Protect Patient CareEven as MGB pays its CEO $9.2 million and makes nearly $3 billion in profits, it refuses to bargain without preconditions, potentially forcing the largest nurses' strike in MA history — The Massachusetts Nurses Association (MNA), representing...
- PlentisoftGrapple Law Publishes New Story That Reveals 6 of 10 Discrimination-Related Job Losses Cite Mental HealthGrapple Law, an employment law AI service, recently published an article that looked at discrimination-related job losses and discovered that 60% of them are related to the employee's mental health. These figures were taken from research by the firm's sister company, Monaco Solicitors, which analysed employment discrimination cases from January 2024 to the end of June 2026.Grapple Law Publishes New Story That Reveals 6 of 10...
- SironaxSironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026Recognized for bold approach to addressing therapeutic targets
- Science CorporationScience Corp. Announces Long-Term (36 Months) Results of PRIMA BCI Clinical Trial Showing Durable Vision Restoration in Blind Patients Suffering from Geographic AtrophyALAMEDA, Calif., October 05, 2026--Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced long-term (36 months) followup data from its pivotal PRIMAvera clinical trial (NCT04676854). The results were presented in a late-breaking session at the 26th EURETINA Congress of European retina specialists in Vienna by Mahi Muqit, MD, PhD, Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust and Associate Professor at the Institu
- U.S. Renal CareU.S. Renal Care & Satellite Healthcare Honor 25 Nurses with National DAISY Award During Nephrology Nurses WeekNurses are recognized for exceptional clinical care, compassion, and commitment to patients — U.S. Renal Care (USRC), the nation's fastest-growing dialysis provider and an industry leader in clinical quality and patient experience, is proud to...
- Anixa Biosciences, Inc.Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialFirst patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 -- Anixa...
- Se lanza la International Brain Health Coalition para poner en práctica estrategias de eficacia comprobadaLíderes mundiales de los sectores de la medicina, las ciencias de la vida, la tecnología, las finanzas y las Naciones Unidas se unen para llevar la evidencia científica sobre la salud cerebral a los hogares, las comunidades y los sistemas de salud, transformando así la evidencia en...
- Consano BioConsano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic Clinical data expected in 1H 2027 — Consano Bio, Inc., a clinical-stage biotechnology company...